MX2022015129A - Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. - Google Patents
Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.Info
- Publication number
- MX2022015129A MX2022015129A MX2022015129A MX2022015129A MX2022015129A MX 2022015129 A MX2022015129 A MX 2022015129A MX 2022015129 A MX2022015129 A MX 2022015129A MX 2022015129 A MX2022015129 A MX 2022015129A MX 2022015129 A MX2022015129 A MX 2022015129A
- Authority
- MX
- Mexico
- Prior art keywords
- neoantigen
- complex
- methods
- antibodies targeting
- classical hla
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 abstract 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se proporcionan anticuerpos que se unen selectivamente al complejo que comprende un HLA-I no clásico (por ejemplo, HLA-E) y un neoantígeno que tiene dominios variables de la cadena pesada (VH), dominios variables de la cadena ligera (VL) y regiones determinantes de complementariedad (CDR) como se divulga en el presente documento, así como métodos y usos de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032886P | 2020-06-01 | 2020-06-01 | |
US17/199,258 US11976120B2 (en) | 2020-06-01 | 2021-03-11 | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
PCT/US2021/035291 WO2021247608A1 (en) | 2020-06-01 | 2021-06-01 | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015129A true MX2022015129A (es) | 2023-03-24 |
Family
ID=78829884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015129A MX2022015129A (es) | 2020-06-01 | 2021-06-01 | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11976120B2 (es) |
EP (1) | EP4157884A4 (es) |
JP (1) | JP2023530037A (es) |
KR (1) | KR20230019469A (es) |
CN (1) | CN116157157A (es) |
AU (1) | AU2021283201A1 (es) |
BR (1) | BR112022023933A2 (es) |
CA (1) | CA3174102A1 (es) |
CL (1) | CL2022003299A1 (es) |
CO (1) | CO2022018430A2 (es) |
CR (1) | CR20220650A (es) |
DO (1) | DOP2022000265A (es) |
EC (1) | ECSP22097203A (es) |
IL (1) | IL298061A (es) |
MX (1) | MX2022015129A (es) |
PE (1) | PE20230374A1 (es) |
WO (1) | WO2021247608A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019309948A1 (en) * | 2018-07-23 | 2021-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
WO2023150092A2 (en) * | 2022-02-01 | 2023-08-10 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to cd276 polypeptides |
TW202413410A (zh) * | 2022-08-18 | 2024-04-01 | 英商英美偌科有限公司 | 多域結合分子 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP2998320B1 (en) | 2011-04-19 | 2018-07-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
WO2015095392A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
CN103773775B (zh) | 2014-01-26 | 2015-11-18 | 江苏省农业科学院 | 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用 |
JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
SG11201705496SA (en) | 2015-01-08 | 2017-08-30 | Genmab As | Bispecific antibodies against cd3 and cd20 |
MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
EP3573997A4 (en) | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
EP3755371A4 (en) | 2018-02-23 | 2021-11-24 | Abexxa Biologics, Inc. | ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN |
AU2019309948A1 (en) | 2018-07-23 | 2021-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2021
- 2021-03-11 US US17/199,258 patent/US11976120B2/en active Active
- 2021-06-01 IL IL298061A patent/IL298061A/en unknown
- 2021-06-01 MX MX2022015129A patent/MX2022015129A/es unknown
- 2021-06-01 JP JP2023517830A patent/JP2023530037A/ja active Pending
- 2021-06-01 PE PE2022002747A patent/PE20230374A1/es unknown
- 2021-06-01 BR BR112022023933A patent/BR112022023933A2/pt not_active Application Discontinuation
- 2021-06-01 EP EP21818757.3A patent/EP4157884A4/en active Pending
- 2021-06-01 US US18/000,493 patent/US20230303701A1/en active Pending
- 2021-06-01 WO PCT/US2021/035291 patent/WO2021247608A1/en active Application Filing
- 2021-06-01 CN CN202180057675.8A patent/CN116157157A/zh active Pending
- 2021-06-01 CA CA3174102A patent/CA3174102A1/en active Pending
- 2021-06-01 CR CR20220650A patent/CR20220650A/es unknown
- 2021-06-01 KR KR1020227046390A patent/KR20230019469A/ko unknown
- 2021-06-01 AU AU2021283201A patent/AU2021283201A1/en active Pending
-
2022
- 2022-11-24 DO DO2022000265A patent/DOP2022000265A/es unknown
- 2022-11-24 CL CL2022003299A patent/CL2022003299A1/es unknown
- 2022-12-19 CO CONC2022/0018430A patent/CO2022018430A2/es unknown
- 2022-12-23 EC ECSENADI202297203A patent/ECSP22097203A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022003299A1 (es) | 2023-07-07 |
EP4157884A1 (en) | 2023-04-05 |
AU2021283201A1 (en) | 2023-02-02 |
WO2021247608A1 (en) | 2021-12-09 |
PE20230374A1 (es) | 2023-03-06 |
CN116157157A (zh) | 2023-05-23 |
KR20230019469A (ko) | 2023-02-08 |
CA3174102A1 (en) | 2021-12-09 |
US20220033504A1 (en) | 2022-02-03 |
US11976120B2 (en) | 2024-05-07 |
EP4157884A4 (en) | 2024-06-19 |
BR112022023933A2 (pt) | 2023-04-11 |
JP2023530037A (ja) | 2023-07-12 |
CO2022018430A2 (es) | 2022-12-30 |
ECSP22097203A (es) | 2023-02-28 |
DOP2022000265A (es) | 2023-01-15 |
IL298061A (en) | 2023-01-01 |
US20230303701A1 (en) | 2023-09-28 |
CR20220650A (es) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015129A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. | |
MX2022015114A (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso. | |
PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
MX2020007880A (es) | Anticuerpos de mica/b y metodos de uso. | |
IL299221A (en) | CD3 binding antibodies | |
AU2013341349A8 (en) | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules | |
PH12021550232A1 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
NZ602320A (en) | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies | |
NZ584658A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
MX2009009782A (es) | Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas. | |
MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
MX2016004928A (es) | Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus. | |
AR122502A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso | |
CY1121950T1 (el) | Νεα αντισωματα εναντι φωσφορυλχολινης | |
FR3061716B1 (fr) | Nouveaux composes ciblant le cd160 humain | |
WO2022026807A3 (en) | Antibodies targeting sars-cov-2 and uses thereof | |
AR122257A2 (es) | Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos | |
WO2023028548A3 (en) | Bispecific tetravalent antibody targeting egfr and her3 | |
MX2024004145A (es) | Terapia del cancer dirigida a nkg2a. | |
TH93924B (th) | โมเลกุลแอนติบอดีซึ่งเชื่อมจับ il-17 ของมนุษย์ |